{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:24:46Z","timestamp":1791854686236,"version":"4.3.4"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Cold-reactive autoimmune hemolytic anemia (AIHA) is rare among the hemolytic anemias. It results when 1 of a variety of processes causes the generation of immunoglobulin M (IgM) autoantibodies against endogenous erythrocytes, resulting in complement activation and predominantly intravascular hemolysis. Cold AIHA is typically a primary lymphoproliferative disorder with marrow B-cell clones producing pathogenic IgM. More rarely, secondary cold AIHA (cAIHA) can develop from malignancy, infection, or other autoimmune disorders. However, in children cAIHA is typically post infection, mild, and self-limited. Symptoms include a sequelae of anemia, fatigue, and acrocyanosis. The severity of disease is variable and highly dependent on the thermal binding range of the autoantibody. In adults, treatment has most commonly focused on reducing antibody production with rituximab-based regimens. The addition of cytotoxic agents to rituximab improves response rates, but at the expense of tolerability. Recent insights into the cause of cold agglutinin disease as a clonal disorder driven by complement form the basis of newer therapeutic options. While rituximab-based regimens are still the mainstay of therapy, options have now expanded to include complement-directed treatments and other B-cell-directed or plasma-cell-directed therapies.<\/jats:p>","DOI":"10.1182\/hematology.2022000369","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:16:24Z","timestamp":1670602584000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Cold AIHA and the best treatment strategies"],"prefix":"10.1182","volume":"2022","author":[{"given":"Jenny McDade","family":"Despotovic","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor Olmsted","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022121313281625100_hem2022000369C1","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2022121313281625100_hem2022000369C2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2013.091702","article-title":"Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma","volume":"99","author":"Randen","year":"2014","journal-title":"Haematologica"},{"issue":"May","key":"2022121313281625100_hem2022000369C3","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"3","key":"2022121313281625100_hem2022000369C4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bjh.15109","article-title":"How I manage patients with cold agglutinin disease","volume":"181","author":"Berentsen","year":"2018","journal-title":"Br J Haematol"},{"issue":"7 April","key":"2022121313281625100_hem2022000369C5","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2022121313281625100_hem2022000369C6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.hoc.2019.01.005","article-title":"Primary and secondary immune cytopenias: evaluation and treatment approach in children","volume":"33","author":"Kim","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2022121313281625100_hem2022000369C7","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"3","key":"2022121313281625100_hem2022000369C8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.blre.2012.01.002","article-title":"Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia","volume":"26","author":"Berentsen","year":"2012","journal-title":"Blood Rev"},{"issue":"1-2","key":"2022121313281625100_hem2022000369C9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-3083.2001.00960.x","article-title":"Acute phase haemolysis in chronic cold agglutinin disease","volume":"54","author":"Ulvestad","year":"2001","journal-title":"Scand J Immunol"},{"issue":"7","key":"2022121313281625100_hem2022000369C10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2022121313281625100_hem2022000369C11","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"2022121313281625100_hem2022000369C12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2991\/chi.k.200706.001","article-title":"Cold agglutinin disease","volume":"2","author":"Gabbard","year":"2020","journal-title":"Clin Hematol Int"},{"issue":"3","key":"2022121313281625100_hem2022000369C13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jca.20240","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis","volume":"25","author":"Szczepiorkowski","year":"2010","journal-title":"J Clin Apher"},{"issue":"3","key":"2022121313281625100_hem2022000369C14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.seminhematol.2018.04.002","article-title":"Complement activation and inhibition in autoimmune hemolytic anemia: focus on cold agglutinin disease","volume":"55","author":"Berentsen","year":"2018","journal-title":"Semin Hematol"},{"issue":"2","key":"2022121313281625100_hem2022000369C15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3324\/haematol.2020.250522","article-title":"Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study","volume":"106","author":"Fattizzo","year":"2021","journal-title":"Haematologica"},{"issue":"22","key":"2022121313281625100_hem2022000369C16","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia","volume":"129","author":"Go","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2022121313281625100_hem2022000369C17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1182\/blood.2019003809","article-title":"How I treat cold agglutinin disease","volume":"137","author":"Berentsen","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2022121313281625100_hem2022000369C18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2022121313281625100_hem2022000369C19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"issue":"2","key":"2022121313281625100_hem2022000369C20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2022121313281625100_hem2022000369C21","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"17","key":"2022121313281625100_hem2022000369C22","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2022121313281625100_hem2022000369C23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2018-03-835413","article-title":"Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2022121313281625100_hem2022000369C24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2009-09-242917","article-title":"Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib","volume":"115","author":"Carson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"2022121313281625100_hem2022000369C25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"23","key":"2022121313281625100_hem2022000369C26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"2022121313281625100_hem2022000369C27","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/bloodadvances.2018024190","article-title":"Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2022121313281625100_hem2022000369C28","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.4049\/jimmunol.1800998","article-title":"C1s inhibition by BIVV009 (sutimlimab) prevents complement-enhanced activation of autoimmune human B cells in vitro","volume":"202","author":"Nikitin","year":"2019","journal-title":"J Immunol"},{"issue":"9","key":"2022121313281625100_hem2022000369C29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in- human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2022121313281625100_hem2022000369C30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2022121313281625100_hem2022000369C31","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2013-11-536573","article-title":"Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"123","author":"Risitano","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2022121313281625100_hem2022000369C32","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ajh.25960","article-title":"C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab","volume":"95","author":"de Castro","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2022121313281625100_hem2022000369C33","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"2022121313281625100_hem2022000369C34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2019-01-894303","article-title":"Cold agglutinins: fending off the attack","volume":"133","author":"Berentsen","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2022121313281625100_hem2022000369C35","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"key":"2022121313281625100_hem2022000369C36","article-title":"Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy [published online 11 July 2022]","author":"Tomkins","journal-title":"American J Hematol"},{"issue":"March","key":"2022121313281625100_hem2022000369C37","doi-asserted-by":"crossref","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol"},{"key":"2022121313281625100_hem2022000369C38","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-48446-0_22","article-title":"Autoimmune Hemolytic Anemia in the Adolescent Females","author":"Kim","year":"2020"},{"issue":"6","key":"2022121313281625100_hem2022000369C39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.pcl.2013.08.009","article-title":"Diagnosis and management of autoimmune cytopenias in childhood","volume":"60","author":"Teachey","year":"2013","journal-title":"Pediatr Clin North Am"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/90\/2023034\/90despotovic.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/90\/2023034\/90despotovic.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:28:52Z","timestamp":1670938132000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/90\/493557\/Cold-AIHA-and-the-best-treatment-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000369","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}